CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
For the period ended Dec 27, 2025. Filed Feb 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 18, 2026
CRL$345.80-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows for fiscal years
| Fiscal Year | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows relating to operating activities | |||
| Net income (loss) | $(142,163) | $25,291 | $480,370 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||
| Depreciation and amortization | 403,312 | 361,741 | 314,124 |
| Goodwill impairment | 165,000 | 215,000 | — |
| Long-lived asset impairments | 259,080 | 51,825 | 41,911 |
| Stock-based compensation | 71,083 | 69,891 | 72,048 |
| Deferred income taxes | (75,292) | (67,428) | (50,903) |
| Write down of inventories | 12,444 | 46,992 | 6,290 |
| (Gains) losses and impairments on venture capital and strategic equity investments, net | 24,911 | 12,910 | (97,827) |
| Provision for credit losses | 6,062 | 14,774 | 18,225 |
| (Gain) loss on divestitures, net | (3,376) | 659 | 961 |
| Other, net | 2,504 | 33,251 | 1,079 |
| Changes in assets and liabilities: | |||
| Trade receivables and contract assets, net | 35,737 | 21,612 | (33,434) |
| Inventories | (48,777) | 16,804 | (62,301) |
| Accounts payable | 2,869 | (14,271) | (20,427) |
| Accrued compensation | 79,308 | (27,604) | 12,447 |
| Deferred revenue | (38,139) | 18,541 | (21,743) |
| Customer contract deposits | 14,652 | 6,584 | (15,564) |
| Other assets and liabilities, net | (31,569) | (51,995) | 38,642 |
| Net cash provided by operating activities | 737,646 | 734,577 | 683,898 |
| Cash flows relating to investing activities | |||
| Capital expenditures | (219,152) | (232,967) | (318,528) |
| Purchases of investments and contributions to venture capital investments | (20,076) | (52,876) | (54,215) |
| Acquisition of businesses and assets, net of cash acquired | — | (5,479) | (194,785) |
| Proceeds from sale of investments | 9,102 | 41,687 | 6,667 |
| Proceeds from sale of businesses, net | 17,441 | — | — |
| Other, net | 3,364 | 4,549 | (2,294) |
| Net cash used in investing activities | (209,321) | (245,086) | (563,155) |
| Cash flows relating to financing activities | |||
| Proceeds from long-term debt and revolving credit facility | 1,227,534 | 1,081,581 | 776,353 |
| Payments on long-term debt, revolving credit facility, and finance lease obligations | (1,349,317) | (1,493,769) | (851,676) |
| Proceeds from exercises of stock options | 714 | 23,878 | 25,597 |
| Purchase of treasury stock | (360,673) | (119,175) | (24,155) |
| Payments of contingent consideration | (21,822) | — | (2,711) |
| Purchase of remaining equity interests of other redeemable noncontrolling interest | (19,140) | (12,000) | (4,784) |
| Other, net | (14,022) | (31,442) | (4,145) |
| Net cash used in financing activities | (536,726) | (550,927) | (85,521) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 18,828 | (17,474) | 8,044 |
| Net change in cash, cash equivalents, and restricted cash | 10,427 | (78,910) | 43,266 |
| Cash, cash equivalents, and restricted cash, beginning of period | 205,570 | 284,480 | 241,214 |
| Cash, cash equivalents, and restricted cash, end of period | $215,997 | $205,570 | $284,480 |
| See Notes to Consolidated Financial Statements. | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.